Paper Details

  1. Home
  2. Paper Details

Treatment of donor bone marrow with monoclonal anti-T-cell antibody and complement for the prevention of graft-versus-host disease. A prospective, randomized, double-blind trial.

Author: ChamplinR E, ElashoffR, GaleR P, GiorgiJ V, HoW G, LenarskyC, MitsuyasuR T, SelchM, WellsJ, WinstonD

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

This study investigated the effects of removing T cells from donor bone marrow before transplantation in 40 patients with leukemia. The study found that removing T cells significantly reduced the incidence of graft-versus-host disease (GVHD), a serious complication of bone marrow transplantation. However, it also increased the risk of graft failure. While relapse rates were similar, the study found evidence of leukemia in those who experienced graft failure. The study concludes that removing T cells from donor bone marrow may reduce GVHD, but further research is needed to determine the long-term effects on graft success and cancer recurrence.
Paper Details　
Original Abstract of the Article :
The effects of ex-vivo depletion of T lymphocytes from donor bone marrow using a monoclonal anti-T-cell antibody (CT-2) and complement on the outcome of allogeneic bone marrow transplantation was evaluated in a prospective, randomized, double-blind study of 40 patients with leukemia. Patients receiv...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.7326/0003-4819-105-1-20

データ提供：米国国立医学図書館（NLM）

Bone Marrow Transplantation: A New Frontier in Treatment

Bone marrow transplantation is a life-saving procedure for individuals with leukemia and other blood disorders. This study investigates the potential of ex-vivo T-cell depletion from donor bone marrow using a monoclonal antibody to reduce the incidence of graft-versus-host disease (GVHD), a serious complication that can occur after transplantation. The researchers conducted a randomized, double-blind trial to evaluate the efficacy of this approach in a group of leukemia patients. The findings suggest that T-cell depletion may be a promising strategy for preventing GVHD, offering a brighter outlook for patients undergoing bone marrow transplantation.

T-Cell Depletion: A Promising Strategy for Preventing GVHD

The study demonstrated a significant reduction in GVHD rates among patients receiving T-cell depleted bone marrow compared to those receiving untreated bone marrow. This suggests that T-cell depletion may be an effective strategy for preventing this life-threatening complication. It's like finding a cool, refreshing spring in a dry desert, offering a much-needed respite from the challenges of GVHD. This research opens doors for safer and more effective bone marrow transplantation procedures.

Living with Bone Marrow Transplantation: A Journey of Hope

Bone marrow transplantation is a complex and demanding treatment, requiring careful management and ongoing support. This study provides a glimmer of hope for individuals facing the challenges of GVHD. The findings suggest that T-cell depletion may offer a valuable tool for mitigating this risk, opening new pathways for safer and more successful transplantation procedures. Remember, hope is like a desert flower, blooming even in the most challenging circumstances.

Dr. Camel's Conclusion

This study offers a promising advancement in bone marrow transplantation, highlighting the potential of T-cell depletion to reduce the incidence of GVHD. It's like finding a hidden oasis in the desert of medical challenges, providing a haven for patients undergoing transplantation. This research paves the way for a brighter future, where transplantation becomes a safer and more effective treatment option for individuals with leukemia and other blood disorders.

Date :
  1. Date Completed 1986-07-22
  2. Date Revised 2019-06-19
Further Info :

Pubmed ID

3521427

DOI: Digital Object Identifier

10.7326/0003-4819-105-1-20

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.